214 related articles for article (PubMed ID: 23184228)
1. Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: effects of polymer dose, PEG coating, and encapsulated anticancer drug.
Saadati R; Dadashzadeh S; Abbasian Z; Soleimanjahi H
Pharm Res; 2013 Apr; 30(4):985-95. PubMed ID: 23184228
[TBL] [Abstract][Full Text] [Related]
2. Non-specific binding and steric hindrance thresholds for penetration of particulate drug carriers within tumor tissue.
Dancy JG; Wadajkar AS; Schneider CS; Mauban JRH; Goloubeva OG; Woodworth GF; Winkles JA; Kim AJ
J Control Release; 2016 Sep; 238():139-148. PubMed ID: 27460683
[TBL] [Abstract][Full Text] [Related]
3. Polydopamine-based surface modification for the development of peritumorally activatable nanoparticles.
Gullotti E; Park J; Yeo Y
Pharm Res; 2013 Aug; 30(8):1956-67. PubMed ID: 23609560
[TBL] [Abstract][Full Text] [Related]
4. Distribution of PLGA-modified nanoparticles in 3D cell culture models of hypo-vascularized tumor tissue.
Sims LB; Huss MK; Frieboes HB; Steinbach-Rankins JM
J Nanobiotechnology; 2017 Oct; 15(1):67. PubMed ID: 28982361
[TBL] [Abstract][Full Text] [Related]
5. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats.
Li Y; Pei Y; Zhang X; Gu Z; Zhou Z; Yuan W; Zhou J; Zhu J; Gao X
J Control Release; 2001 Apr; 71(2):203-11. PubMed ID: 11274752
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of METase-pemetrexed-loaded PEG-PLGA nanoparticles modified with anti-CD133-scFV for treatment of gastric carcinoma.
Xin L; Zhang HT; Yang WF; Li YF; Liu C
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29229675
[TBL] [Abstract][Full Text] [Related]
7. Etoposide loaded PLGA and PCL nanoparticles II: biodistribution and pharmacokinetics after radiolabeling with Tc-99m.
Snehalatha M; Venugopal K; Saha RN; Babbar AK; Sharma RK
Drug Deliv; 2008 Jun; 15(5):277-87. PubMed ID: 18763158
[TBL] [Abstract][Full Text] [Related]
8. Effects of block copolymer properties on nanocarrier protection from in vivo clearance.
D'Addio SM; Saad W; Ansell SM; Squiers JJ; Adamson DH; Herrera-Alonso M; Wohl AR; Hoye TR; Macosko CW; Mayer LD; Vauthier C; Prud'homme RK
J Control Release; 2012 Aug; 162(1):208-17. PubMed ID: 22732478
[TBL] [Abstract][Full Text] [Related]
9. Effect of PEG and water-soluble chitosan coating on moxifloxacin-loaded PLGA long-circulating nanoparticles.
Mustafa S; Devi VK; Pai RS
Drug Deliv Transl Res; 2017 Feb; 7(1):27-36. PubMed ID: 27576453
[TBL] [Abstract][Full Text] [Related]
10. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes.
Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 354(1-2):56-62. PubMed ID: 18083313
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
12. Accelerated Blood Clearance of Nanoemulsions Modified with PEG-Cholesterol and PEG-Phospholipid Derivatives in Rats: The Effect of PEG-Lipid Linkages and PEG Molecular Weights.
Liu M; Chu Y; Liu H; Su Y; Zhang Q; Jiao J; Liu M; Ding J; Liu M; Hu Y; Dai Y; Zhang R; Liu X; Deng Y; Song Y
Mol Pharm; 2020 Apr; 17(4):1059-1070. PubMed ID: 31860321
[TBL] [Abstract][Full Text] [Related]
13. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
[TBL] [Abstract][Full Text] [Related]
14. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes.
Shimizu T; Abu Lila AS; Fujita R; Awata M; Kawanishi M; Hashimoto Y; Okuhira K; Ishima Y; Ishida T
Eur J Pharm Biopharm; 2018 Jun; 127():142-149. PubMed ID: 29462689
[TBL] [Abstract][Full Text] [Related]
15. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage.
Abu Lila AS; Kiwada H; Ishida T
J Control Release; 2013 Nov; 172(1):38-47. PubMed ID: 23933235
[TBL] [Abstract][Full Text] [Related]
16. Suitable carriers for encapsulation and distribution of endostar: comparison of endostar-loaded particulate carriers.
Chen W; Hu S
Int J Nanomedicine; 2011; 6():1535-41. PubMed ID: 21845043
[TBL] [Abstract][Full Text] [Related]
17. Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice.
Hashimoto Y; Shimizu T; Abu Lila AS; Ishida T; Kiwada H
Biol Pharm Bull; 2015; 38(3):417-24. PubMed ID: 25757923
[TBL] [Abstract][Full Text] [Related]
18. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.
Gao C; Pan J; Lu W; Zhang M; Zhou L; Tian J
Anticancer Drugs; 2009 Oct; 20(9):807-14. PubMed ID: 19696655
[TBL] [Abstract][Full Text] [Related]
19. Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy.
Yang Q; Ma Y; Zhao Y; She Z; Wang L; Li J; Wang C; Deng Y
Int J Nanomedicine; 2013; 8():1257-68. PubMed ID: 23576868
[TBL] [Abstract][Full Text] [Related]
20. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.
Wang X; Ishida T; Kiwada H
J Control Release; 2007 Jun; 119(2):236-44. PubMed ID: 17399838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
